Cover Image
市場調查報告書

馬來西亞的醫藥品、醫療產業(季度更新報告)

Malaysia Pharmaceuticals and Healthcare Report Q4 2017

出版商 BMI Research 商品編碼 179529
出版日期 內容資訊 英文 94 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
馬來西亞的醫藥品、醫療產業(季度更新報告) Malaysia Pharmaceuticals and Healthcare Report Q4 2017
出版日期: 2017年09月13日 內容資訊: 英文 94 Pages
簡介

馬來西亞的醫藥品、醫療產業持續大幅成長,政府對醫療領域的預算擴大,加上人口的增加及疾病的負擔等要素促進醫療需求,今後前景明亮。還有多年的談判結束,預期TPP協定簽訂對該國市場,尤其是跨國公司對專利藥的關注高漲。

本報告提供馬來西亞的製藥、醫療產業結構和最新趨勢相關分析,今後10年的產業規模的動向估計,產業課題(風險)和未來商機(利潤)相關評估,政府的政策、規定,宏觀經濟環境,主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用醫藥品(成藥)市場預測
  • 醫藥品的對外貿易情形

產業的風險/利潤、等級

  • 亞洲:風險/利潤、等級
  • 馬來西亞:風險/利潤、等級
    • 利潤
    • 風險

市場概況

  • 流行病學
  • 醫療部門
  • 醫療保險
  • 醫療部門的資金籌措
  • 醫療部門的發展
  • 醫療觀光
  • 研究開發(R&D)
  • 臨床實驗

法規概要

  • 管理體制
  • 法規的發展
  • 知識產權相關課題
  • 價格設定的體制

競爭環境

  • 國內產業
  • 外資產業
  • 傳統醫藥品
  • 醫藥品的流通結構
  • 醫藥品的零售部門

企業簡介

  • Chemical Company Of Malaysia
  • Kotra Pharma
  • Novartis
  • Ranbaxy Malaysia
  • Sanofi

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 等級概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-2038

BMI View: Concerns over the price of pharmaceuticals will remain a key theme in Malaysia for the

foreseeable future. Elevated medicine prices in Malaysia will continue to drive demand for pharmaceutical

price regulation given the current lack of adequate regulation. The government's proposed legislation

hopes to control prices; this will be positive for both the drugmakers and patients, enabling greater access

to medicines.

Headline Expenditure Projections

Pharmaceuticals: MYR8.60bn (USD2.07bn) in 2016 to MYR8.99bn (USD2.12bn) in 2017; +4.5% in

local currency and 2.0% in US dollar terms. Forecast revised upwards in US dollar terms.

Healthcare: MYR54.65bn (USD13.18bn) in 2016 to MYR59.99bn (USD14.12bn) in 2017; +9.8% in

local currency and +7.1% in US dollar terms. Forecast revised upwards in US dollar terms.

Risk/Reward Index

Malaysia's growing population and a rising non-communicable disease burden results in the country scoring

59.1 out of 100 in BMI's Innovative Pharmaceuticals Risk/Reward Index. While there is an increased

market access to new drugs, owing to greater international collaboration and free trade agreements, the

focus on cost-efficiency within the healthcare sector will limit the market's growth potential.

Table of Contents

  • BMI Industry View
    • Table: Headline Pharmaceuticals & Healthcare Forecasts (Malaysia 2015-2021)
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2013-2021)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2013-2021)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2013-2021)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2013-2021)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2013-2021)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2013-2021)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2013-2021)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Malaysia 2013-2021)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2015-2021)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2015-2021)
  • Industry Risk/Reward Index
  • Asia Pacific Pharmaceuticals: Diverse Opportunities And Inherent Risks
  • Malaysia Risk/Reward Index - Q4 2017
  • Reward
  • Risk
  • Regulatory Review
  • Intellectual Property Issues
  • Pricing Regime
  • Market Overview
  • Healthcare Sector
    • Table: Healthcare Resources (Malaysia 2011-2016)
    • Table: Healthcare Personnel (Malaysia 2011-2016)
    • Table: Healthcare Activity (Malaysia 2011-2016)
  • Healthcare Insurance
    • Table: Main Features Of 1Care
  • Medical Tourism
  • Research & Development
  • Clinical Trials
  • Epidemiology

Competitive Landscape

  • Research-Based Industry
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Culture-Specific Medicines
  • Pharmaceutical Distribution
    • Table: Drug Wholesalers & Importers, 2002-2010
  • Pharmaceutical Retail Sector
  • Company Profile
  • Chemical Company Of Malaysia
  • Kotra Pharma
  • Novartis
  • Ranbaxy Malaysia
  • Sanofi
  • Demographic Forecast
  • Demographic Outlook
    • Table: Population Headline Indicators (Malaysia 1990-2025)
    • Table: Key Population Ratios (Malaysia 1990-2025)
    • Table: Urban/Rural Population & Life Expectancy (Malaysia 1990-2025)
    • Table: Population By Age Group (Malaysia 1990-2025)
    • Table: Population By Age Group % (Malaysia 1990-2025)
  • Glossary
  • Methodology
  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
    • Table: Indicators - Rationale And Sources
Back to Top